N/A
N=76
Proteiomic Fingerprints of Gastric Juice
Gastric Cancer
Bottom Line
View on ClinicalTrials.gov: NCT00834236 ↗Enrolled (actual)
76
Serious AEs
0.0%
Results posted
Dec 2015
Primary outcome: Primary: Number of Participants With Accurate Diagnosis for Gastric Cancer — 27; 44 participants
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- normal subject (Other); gastric cancer (Other)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Kaohsiung Veterans General Hospital.
- Primary completion
- Mar 2011
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants With Accurate Diagnosis for Gastric Cancer |
27; 44 | — |
Summary
No accurate, inexpensive and non-invasive test for gastric cancer screening is currently available. The investigators' recent study identified a1-antitrypsin and other proteins as potential biomarkers of gastric cancer in gastric juice. The aim of this study was to develop a novel non-invasive modality for detecting gastric cancer by measurement of biomarkers in gastric juice.
Eligibility Criteria
Inclusion Criteria
- healthy subjects and gastric cancer patients documented by endoscopy.
Exclusion Criteria
- the use of proton pump inhibitors or histamine-2 receptor antagonists within 4 weeks prior to the study
- coexistence of two kinds of gastroduodenal lesions
- coexistence of severe systemic diseases
Data sourced from ClinicalTrials.gov (NCT00834236). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.